嵌合抗原受体
实体瘤
癌症研究
医学
细胞
细胞疗法
癌症治疗
癌症
免疫疗法
生物
内科学
遗传学
作者
Keyvan Kheyrolahzadeh,Mohammad Reza Tohidkia,Ali Tarighatnia,Parviz Shahabi,Nader D. Nader,Ayuob Aghanejad
出处
期刊:Life Sciences
[Elsevier]
日期:2023-09-01
卷期号:328: 121917-121917
被引量:6
标识
DOI:10.1016/j.lfs.2023.121917
摘要
Cell therapy has reached significant milestones in various life-threatening diseases, including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor (CAR)-T cell is a successful strategy for diagnosing or treating malignancies. Since cell therapy approaches have different results in cancers, the success of hematological cancers has yet to transfer to solid tumor therapy, leading to more casualties. Therefore, there are many areas for improvement in the cell therapy platform. Understanding the therapeutic barriers associated with solid cancers through cell tracking and molecular imaging may provide a platform for effectively delivering CAR-T cells into solid tumors. This review describes CAR-T cells' role in treating solid and non-solid tumors and recent advances. Furthermore, we discuss the main obstacles, mechanism of action, novel strategies and solutions to overcome the challenges from molecular imaging and cell tracking perspectives.
科研通智能强力驱动
Strongly Powered by AbleSci AI